Soliris

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office*

Drug Information:

*Strength/Measure*_____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un
*Directions(sig)*_____ *Route of administration*_____
*Dosing frequency*_____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Criteria Questions:

1. What is the patient's diagnosis?
   - ❑ Atypical hemolytic uremic syndrome (aHUS)
   - ❑ Paroxysmal nocturnal hemoglobinuria (PNH)
   - ❑ Generalized myasthenia gravis (gMG)
   - ❑ Neuromyelitis optica spectrum disorder (NMOSD)
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. What is the patient's weight? _____kg
4. Is this a request for continuation of therapy? ❑ Yes ❑ No *If No, skip to diagnosis section.*
5. Is there evidence of unacceptable toxicity or disease progression while on the current regimen? ❑ Yes ❑ No
6. Has the patient experienced a positive response to therapy by any of the following? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation supporting positive clinical response to therapy.***
   - ❑ normalization of lactate dehydrogenase [LDH] levels, platelet counts
   - ❑ improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels
   - ❑ improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis [QMG] total score
   - ❑ reduction in number of relapses (NMOSD)
   - ❑ None of the above
7. *For the diagnosis of NMOSD,* will the patient receive the requested drug concomitantly with other biologics for the treatment of neuromyelitis optica spectrum disorder (NMOSD)? ❑ Yes ❑ No
8. What is the prescribed maintance dose and frequency? _____ mg every _____ weeks *No further questions*

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Atypical Hemolytic Uremic Syndrome (aHUS)

9. Is the disease caused by Shiga toxin? ❑ Yes ❑ No
10. Do tests confirm the absence of Shiga toxin? ❑ Yes ❑ No
11. What is the ADAMTS13 level? ***ACTION REQUIRED: Please attach documentation of ADAMTS13 level.*** _____ %
12. What is the prescribed loading dose and frequency? Quantity and Frequency: _____
13. What is the prescribed maintenance dose and frequency? Quantity and Frequency:_____

Section B: Paroxysmal Nocturnal Hemoglobinuria (PNH)

14. Was the diagnosis of PNH confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs)? ❑ Yes ❑ No
15. Was flow cytometry used to demonstrate the deficiency of GPI-anchored proteins? ***ACTION REQUIRED: If 'Yes', please attach flow cytometry report.*** ❑ Yes ❑ No
16. How was the diagnosis established?
    - ❑ Quantification of PNH cells
    - ❑ Quantification of GPI-anchored protein deficient poly-morphonuclear cells, *skip to #18*
    - ❑ None of the above
17. What was the percentage of PNH cells? _____***%*** *skip to #19*

Send completed form to: Priority Partners Fax: 1-866-212-4756

18. What was the percentage of GPI-anchored protein deficient poly-morphonuclear cells? _____***%***

19. Does the prescribed dose exceed a loading dose of 600 mg weekly for 4 weeks followed by a fifth dose of 900 mg one week later? ❑ Yes ❑ No

20. Does the prescribed dose exceed a maintenance dose of 900 mg? ❑ Yes ❑ No

21. Is the prescribed frequency for the maintenance dose more frequent than one dose every 2 weeks? ❑ Yes ❑ No

Section C: Generalized Myasthenia Gravis (gMG)

22. Is Soliris being used to treat a patient who is anti-acetylcholine receptor (AchR) antibody positive?
ACTION REQUIRED: If 'Yes', please attach documentation of AchR antibody testing. ❑ Yes ❑ No

23. What is the patient's Myasthenia Gravis Foundation of America (MGFA) clinical classification?
ACTION REQUIRED: Please attach documentation of MGFA clinical classification.
❑ Class I ❑ Class II ❑ Class III ❑ Class IV ❑ Class V ❑ Unknown

24. What is the patient's score on the MG activities of daily living? ***ACTION REQUIRED: Please attach documentation of MG-ADL score. _____***

25. Has the patient had an inadequate response to at ANY immunosuppressive therapies listed below?
ACTION REQUIRED: If 'Yes', please attach documentation of inadequate response to the immunosuppressive therapies. *Indicate ALL that apply.*
❑ Azathioprine
❑ Methotrexate
❑ Cyclophosphamide
❑ Cyclosporine
❑ Mycophenolate mofetil
❑ Tacrolimus
❑ None of the above

26. Has the patient experienced an inadequate response to chronic intravenous immunoglobulins (IVIG) AND rituximab? ***ACTION REQUIRED: If 'Yes', please attach documentation of inadequate response to both IVIG and rituximab.*** ❑ Yes ❑ No

27. Does the prescribed dose exceed a loading dose of 900 mg weekly for 4 weeks followed by a fifth dose of 1200 mg one week later? ❑ Yes ❑ No

28. Does the prescribed dose exceed a maintenance dose of 1200 mg? ❑ Yes ❑ No

29. Is the prescribed frequency for the maintenance dose more frequent than one dose every 2 weeks? ❑ Yes ❑ No

Section D: Neuromyelitis Optica Spectrum Disorder (NMOSD)

30. Is the patient anti-aquaporin-4 (AQP4) antibody positive? ***ACTION REQUIRED: If 'Yes', please attach immunoassay confirming presence of anti-AQP4 antibody.*** ❑ Yes ❑ No

31. Does the patient exhibit at least one of the core clinical characteristics of NMOSD?
❑ Optic neuritis
❑ Acute myelitis
❑ Area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting)
❑ Acute brainstem syndrome
❑ Symptomatic cerebral syndrome with NMOSD-typical brain lesions
❑ Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
❑ None of the above

32. Will the patient receive the requested drug concomitantly with other biologics for the treatment of neuromyelitis optica spectrum disorder (NMOSD)? ❑ Yes ❑ No

33. Does the prescribed dose exceed a loading dose of 900 mg weekly for 4 weeks followed by a fifth dose of 1200 mg one week later? ❑ Yes ❑ No

Send completed form to: Priority Partners Fax: 1-866-212-4756

34. Does the prescribed dose exceed a maintenance dose of 1200 mg? ❑ Yes ❑ No

35. Is the prescribed frequency for the maintenance dose more frequent than one dose every 2 weeks? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756